Patents by Inventor Zhu Alexander Cao
Zhu Alexander Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230044943Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.Type: ApplicationFiled: May 16, 2022Publication date: February 9, 2023Inventors: Giordano Caponigro, Zhu Alexander Cao
-
Patent number: 11376239Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.Type: GrantFiled: September 24, 2019Date of Patent: July 5, 2022Assignee: ARRAY BIOPHARMA INCInventors: Giordano Caponigro, Zhu Alexander Cao
-
Publication number: 20210000951Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.Type: ApplicationFiled: May 19, 2020Publication date: January 7, 2021Inventors: Zhu Alexander Cao, Xianhui Rong, Maria Consuelo Pinzon-Ortiz, Tyler Longmire, Benjamin Hyun Lee
-
Publication number: 20200230108Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.Type: ApplicationFiled: September 24, 2019Publication date: July 23, 2020Inventors: Giordano Caponigro, Zhu Alexander Cao
-
Publication number: 20200030442Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.Type: ApplicationFiled: March 8, 2019Publication date: January 30, 2020Inventor: Zhu Alexander Cao
-
Patent number: 10485788Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.Type: GrantFiled: December 3, 2018Date of Patent: November 26, 2019Assignee: Array BioPharma Inc.Inventors: Giordano Caponigro, Zhu Alexander Cao
-
Publication number: 20190290627Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.Type: ApplicationFiled: June 14, 2019Publication date: September 26, 2019Inventors: Zhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
-
Publication number: 20190105303Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.Type: ApplicationFiled: December 3, 2018Publication date: April 11, 2019Inventors: Giordano Caponigro, Zhu Alexander Cao
-
Publication number: 20180071296Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a JAK inhibitor compound, (b) a CDK inhibitor, and (c) a PIM kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.Type: ApplicationFiled: September 20, 2017Publication date: March 15, 2018Inventors: Zhu Alexander Cao, Maria PINZON-ORTIZ, Xianhui RONG
-
Publication number: 20170368044Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.Type: ApplicationFiled: September 7, 2017Publication date: December 28, 2017Applicant: NOVARTIS AGInventors: Zhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
-
Publication number: 20170340733Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.Type: ApplicationFiled: December 18, 2015Publication date: November 30, 2017Applicant: NOVARTIS AGInventor: Zhu Alexander Cao
-
Publication number: 20170209574Abstract: Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. The combination may comprise an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is an inhibitor of an immune checkpoint molecule chosen from the list of inhibitors of one or more of PD-1, PD L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or the immunomodulator is an activator of a costimulatory molecule chosen from the list of agonists of one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand, and wherein (ii) the second therapeutic agent is chosen from one or more compounds as provided in Table 1, i.e. LCL 161, Rad-001 (Evrolimus), CGM097, LGH-447, LJM716 (Human monoclonal antibody), LB-H589 (Panobinostat), INC424 (Ruxolitinib), BUW078 or BGJ398.Type: ApplicationFiled: October 2, 2015Publication date: July 27, 2017Inventors: Zhu Alexander Cao, Xianhui Rong, Maria Consuelo Pinzon-Ortiz, Tyler Longmire, Benjamin Hyun Lee
-
Publication number: 20170157134Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.Type: ApplicationFiled: February 15, 2017Publication date: June 8, 2017Inventors: Qing Sheng, Hui-Qin Wang, Fang Li, Jinsheng Liang, Zhu Alexander Cao, John Monahan, Richard Versace
-
Publication number: 20160375024Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a JAK inhibitor compound, (b) a CDK inhibitor, and (c) a PIM kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.Type: ApplicationFiled: November 25, 2014Publication date: December 29, 2016Applicant: Novartis AGInventors: Zhu Alexander CAO, Maria PINZON-ORTIZ, Xianhui RONG
-
Publication number: 20160287605Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.Type: ApplicationFiled: June 16, 2016Publication date: October 6, 2016Applicant: Novartis AGInventors: Qing Sheng, Hui-Qin Wang, Fang Li, Jinsheng Liang, Zhu Alexander Cao, John Monahan, Richard Versace
-
Publication number: 20160175293Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.Type: ApplicationFiled: August 7, 2014Publication date: June 23, 2016Applicant: NOVARTIS AGInventors: Zhu Alexander CAO, Abdel SACCI, K. Gary J, VANASSE, Joseph GROWNEY
-
Publication number: 20150290204Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.Type: ApplicationFiled: November 6, 2013Publication date: October 15, 2015Applicant: Novartis AGInventors: Qing Sheng, Hui-Qin Wang, Fang Li, Jinsheng Liang, Zhu Alexander Cao, John Monahan, Richard Versace
-
Patent number: 8980259Abstract: The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an insulin-like growth factor-1 receptor (IGF1R) inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.Type: GrantFiled: March 13, 2013Date of Patent: March 17, 2015Assignees: Novartis AG, Amgen, Inc.Inventors: Xizhong Huang, Malte Peters, Karl Maria Schumacher, Zhu Alexander Cao, Jennifer Lorraine Gansert, David Dong Eun Chang
-
Patent number: 8961970Abstract: The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.Type: GrantFiled: March 13, 2013Date of Patent: February 24, 2015Assignees: Novartis AG, Amgen Inc.Inventors: Xizhong Huang, Malte Peters, Jennifer Lorraine Gansert, David Dong Eun Chang, Pedro Beltran, Zhu Alexander Cao
-
Publication number: 20140023661Abstract: The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.Type: ApplicationFiled: March 13, 2013Publication date: January 23, 2014Applicants: Amgen, Inc., Novartis Pharma AGInventors: Xizhong Huang, Malte Dong Eun Peters, Karl Maria Schumacher, Zhu Alexander Cao, Jennifer Lorraine Gansert, David Dong Eun Chang